Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-12-19 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used for a "PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" in the context of a takeover offer. This type of filing relates directly to insider/significant shareholder activity during a takeover scenario. While it involves dealing disclosures, the specific context of the Takeover Code (Rule 8.3) points towards activity related to a potential merger or takeover bid. Therefore, the most appropriate category is M&A Activity (TAR), as this disclosure is triggered by the takeover process.
2023-12-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number'. It details changes in voting rights held by a shareholder (Societe Generale) in the issuer (Dechra Pharmaceuticals PLC), specifically noting the date the threshold was crossed and the resulting total positions. This structure perfectly matches the definition of a Director's Dealing or Major Shareholding Notification. Since the notification is about a major shareholder crossing a threshold (8.329500% ownership), the most appropriate code is MRQ (Major Shareholding Notification). Although it is a regulatory filing, MRQ is more specific than RNS.
2023-12-19 English
Rule 2.9 Announcement
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Rule 2.9 Announcement' made by Dechra Pharmaceuticals PLC in accordance with the 'City Code on Takeovers and Mergers (the "Code")'. Rule 2.9 requires confirmation of the total number of shares in issue when a company is subject to a takeover offer. This type of announcement, related to takeover activity and regulatory disclosure under the Takeover Code, is most closely aligned with M&A Activity (TAR) or, given its nature as a specific regulatory disclosure related to a potential transaction, it could also be considered a general Regulatory Filing (RNS). Since 'TAR' specifically covers merger proposals or takeover bids, and this announcement is a direct consequence of the rules governing such an event (confirming share count during an offer period), TAR is the most precise fit. The document is short and is a formal regulatory disclosure, not a comprehensive report.
2023-12-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 2103X" and contains the header "National Storage Mechanism". The content details a "TR-1: Standard form for notification of major holdings" by Societe Generale regarding an acquisition of voting rights in DECHRA PHARMACEUTICALS PLC, crossing a threshold on 15-Dec-2023. This type of mandatory disclosure regarding changes in significant share ownership directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-12-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is dated 18 December 2023. It details changes in voting rights held by JPMorgan Chase & Co. and its subsidiaries, specifically noting the crossing of a threshold on 14-Dec-2023. This structure and content are characteristic of regulatory filings related to insider or major shareholder transactions/holdings, which in the UK context often fall under Disclosure Guidance and Transparency Rules (DTR). Since this is a specific regulatory notification about share ownership changes and not a general earnings release, annual report, or management change announcement, it fits best under the 'Major Shareholding Notification' category (MRQ) or potentially the general 'Regulatory Filings' (RNS) if MRQ was not available. Given the specific definition of MRQ as 'Notification of changes in significant share ownership levels (crossing thresholds)', MRQ is the most precise fit.
2023-12-18 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose personal share transactions or holdings by parties involved in a takeover bid, which falls under insider trading or director/executive dealing disclosures, specifically related to M&A activity contextually, but the core mechanism is reporting personal security interests/dealings. Among the provided codes, 'DIRS' (Director's Dealing) is the closest fit for reporting personal share transactions by executives/insiders, even though this specific form (Form 8.3) is mandated by the Takeover Code and relates to an ongoing offer (M&A context). However, since the document details the interests and dealings of 'Millennium International Management LP' in 'Dechra Pharmaceuticals plc' during a potential offer period, it is a specific type of insider transaction disclosure. Given the options, 'DIRS' covers personal share transactions by insiders. If the context were purely M&A, 'TAR' might apply, but this is a mandatory disclosure of a position/dealing, which aligns best with the spirit of 'DIRS' (insider trading/dealing reports). Since it is a mandatory disclosure of personal dealings/interests by a significant holder related to a potential offer, and 'DIRS' covers personal share transactions by directors/executives, I will classify it as DIRS, as it is a direct report of security interests and dealings by an involved party.
2023-12-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.